Cardio Diagnostics Holdings (CDIO) Other financing activities (2021 - 2023)

Cardio Diagnostics Holdings (CDIO) posted Other financing activities of $390000.0 for Q1 2023, up 7978.79% sequentially from -$4950.0 in Q4 2022.

Cardio Diagnostics Holdings (CDIO) Other financing activities (2021 - 2023) Analysis & Trends

Cardio Diagnostics Holdings has reported Other financing activities for 3 years, with the latest figure at $390000.0 in Q1 2023.

Quarterly Other financing activities changed N/A year-over-year to $390000.0 in Q1 2023, while the trailing twelve-month figure through Dec 2023 was $390000.0 (up 7978.79% YoY) and the FY2023 annual result came in at $390000.0, up 7978.79% from the prior year.
Other financing activities grew to $390000.0 in Q1 2023 per CDIO's latest filing, from -$4950.0 in the prior quarter.
Over five years, Other financing activities peaked at $65.0 million in Q4 2021 and troughed at -$4950.0 in Q4 2022.
A 3-year average of $21.8 million and a median of $390000.0 in 2023 frame the typical range for Other financing activities.
The widest YoY moves for Other financing activities: up 100.01% in 2022, down 100.01% in 2022.
Over 3 years, Other financing activities stood at $65.0 million in 2021, then tumbled by 100.01% to -$4950.0 in 2022, then soared by 7978.79% to $390000.0 in 2023.
According to Business Quant data, Other financing activities over the past three periods registered $390000.0, -$4950.0, and $65.0 million for Q1 2023, Q4 2022, and Q4 2021 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Cardio Diagnostics Holdings	6.42 Mn	835,350.96	-

Download Data